FHND9041 capsule 80 mg shows significant antitumor activity with favorable efficacy and safety profile in patients for both initial treatment and treatment of T790M+ NSCLC who progressed after prior therapy. For futher research of the capsule, a multicenter, randomized, positive-controlled phase III clinical research is ongoing with recommended dose of 80 mg.GroupDosage(mg)Evaluable Subjects(n)ORR%Second/Third-line T790M+40mg333.3380mg3963.64120mg4258.33180mg3100.00First-line80mg3771.43